The Polymyositis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Polymyositis Market?
The market size for polymyositis has seen substantial growth in the past few years. It is set to increase from $1.65 billion in 2024 to $1.75 billion in 2025, with a compound annual growth rate (CAGR) of 6.4%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Polymyositis Industry?
The Polymyositis Global Market Report 2025 projects that by 2029, the market size will increase to $2.23 billion, growing at a compound annual growth rate (CAGR) of 6.2%.
Download Your Free Sample of the 2025 Polymyositis Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Polymyositis Market?
The key drivers in the polymyositis market are:
• Expansion in telemedicine and remote monitoring practices
• The rise in utilization of immunosuppressants
• Increase in the use of stem cell therapy and biosimilars
• Integration of artificial intelligence in drug discovery and advancements in targeted therapies.
Global Market Segmentation: Identifying Major Polymyositis Industry Segments
The polymyositis market covered in this report is segmented –
1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes
2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI)
3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies
4) By Distribution Channel: Offline, Online
5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy
Subsegments:
1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis
2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis
3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy
4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)
Pre-order the 2025 Polymyositis Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Polymyositis Market?
The key trends in the polymyositis market are:
• The integration of artificial intelligence in drug discovery is an emerging trend.
• Advancements in targeted therapies are shaping the market.
• The development of novel immunomodulators is a significant forecasted trend.
• The use of big data in the healthcare sector is an up-and-coming trend.
Who Are the Top Competitors & Leading Players in the Polymyositis Market?
Major players in the polymyositis market are:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc
• Merck & Co. Inc.
• C.H. Boehringer Sohn AG & Co. KG
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Fresenius SE & Co. KGaA
• UCB S.A.
• Reliance Life Sciences Private Limited
• ARUP Laboratories
• Teva Pharmaceuticals USA Inc.
• Kezar Life Sciences Inc.
• Argenx SE
• Mallinckrodt Pharmaceuticals plc
• Mitsubishi Tanabe Pharma Corporation
• ViiV Healthcare Limited
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the polymyositis market in 2024
